{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang Y"],"funding":["Capital Health Research and Development of Special Fund"],"pagination":["1749-1766"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9588101"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(4)"],"pubmed_abstract":["<h4>Introduction</h4>Clopidogrel resistance causes recurrent stroke. However, outcomes of modified antiplatelet medications to prevent recurrent ischemic stroke are not well known.<h4>Methods</h4>Patients who received clopidogrel with and without modification as initial treatment for stroke were recruited and compared. The primary outcome was ischemic stroke and myocardial infarction at the 1-year follow-up. The secondary outcome was bleeding complications.<h4>Results</h4>Overall, 206 patients treated with clopidogrel were enrolled and were divided into the modification (n = 39) and no modification (n = 167) groups. There was a significant difference in the incidence of severe cerebral arterial stenosis between the two groups (modification group, 16/39, 41.03%; no modification group, 36/16"],"journal":["Neurology and therapy"],"pubmed_title":["Verifynow P2Y<sub>12</sub> PRU-Guided Modification of Clopidogrel for Prevention of Recurrent Ischemic Stroke: A Real-World Prospective Cohort Study."],"pmcid":["PMC9588101"],"funding_grant_id":["2014-1-4092"],"pubmed_authors":["Qiao S","Zhang Y","Hu H","Fan D"],"additional_accession":[]},"is_claimable":false,"name":"Verifynow P2Y<sub>12</sub> PRU-Guided Modification of Clopidogrel for Prevention of Recurrent Ischemic Stroke: A Real-World Prospective Cohort Study.","description":"<h4>Introduction</h4>Clopidogrel resistance causes recurrent stroke. However, outcomes of modified antiplatelet medications to prevent recurrent ischemic stroke are not well known.<h4>Methods</h4>Patients who received clopidogrel with and without modification as initial treatment for stroke were recruited and compared. The primary outcome was ischemic stroke and myocardial infarction at the 1-year follow-up. The secondary outcome was bleeding complications.<h4>Results</h4>Overall, 206 patients treated with clopidogrel were enrolled and were divided into the modification (n = 39) and no modification (n = 167) groups. There was a significant difference in the incidence of severe cerebral arterial stenosis between the two groups (modification group, 16/39, 41.03%; no modification group, 36/16","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-19T15:40:37.228Z","creation":"2025-04-19T15:40:37.228Z"},"accession":"S-EPMC9588101","cross_references":{"pubmed":["36163415"],"doi":["10.1007/s40120-022-00406-z"]}}